meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cabozantinib
nivolumab based treatment
nivolumab alone
versus all
vs mTOR inhibitors
vs everolimus
vs VEGF(R) inhibitor
vs cabozantinib
All patients
Age < 65y (younger)
Age > 75y (older)
Gender, female
Gender, male
PD-L1 < 1%
PD-L1 > 1%
PD-L1 > 5%
Risk favorable (IMDC)
Risk intermediate (IMDC)
Risk poor (IMDC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
objective responses (ORR) (extension)
progression or deaths (PFS)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Anaemia TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Epistaxis TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Peripheral oedema TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
deaths (OS)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
nivolumab alone vs. everolimus
1
-768 [-1449; -86]
/10000
183/410 vs. 215/411
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open